On July 15, 2026, AtaiBeckley Inc. entered into a definitive merger agreement to be acquired by Eli Lilly and Company. AtaiBeckley shareholders will receive $6.75 per share in cash plus one contingent value right (CVR) per share, which can provide up to an additional $2.50 per share based on clinical and regulatory milestones for BPL-003 and VLS-01. The transaction represents an aggregate upfront equity value of approximately $2.8 billion. The merger is subject to stockholder approval and regulatory clearances, with a termination fee of $104.3 million payable by AtaiBeckley under certain conditions. AtaiBeckley is a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions.

AtaiBeckley Inc. held its annual meeting of stockholders on June 4, 2026, where the election of Class I directors and the first proposal to ratify Deloitte & Touche LLP as its independent registered public accounting firm were both approved. Approximately 366,916,896 shares of common stock were outstanding and entitled to vote, with 203,908,561 shares represented at the quorum.